# Glutathione (GSH) Dosage Protocol Guide — IV, Subcutaneous & Nebulized Research Use (2026)
Glutathione (GSH) is the most abundant intracellular antioxidant in the human body — a tripeptide of glutamate, cysteine, and glycine that coordinates cellular redox balance, Phase II detoxification, and immune defense. Despite its central importance, research protocols for glutathione administration vary dramatically by route: a subcutaneous injection of 200 mg achieves a fundamentally different pharmacokinetic profile than an intravenous infusion of 1,400 mg, and inhaled delivery bypasses systemic distribution entirely to concentrate GSH in bronchial epithelial lining fluid.
This guide consolidates published dosing parameters from peer-reviewed clinical trials and pharmacokinetic studies, organized by route of administration. It is intended for researchers designing glutathione studies, not as prescriptive guidance for personal use.
> Research Use Disclaimer: This article is for research and educational purposes only. Glutathione has no FDA-approved injectable or IV formulation. All injectable and inhalation protocols described here use compounded preparations and are documented from published research. Not intended for human use outside of licensed clinical or research settings. Consult a licensed medical professional for any clinical application.
---
What Is Glutathione and Why Does Route of Administration Matter?
Glutathione exists primarily in two interconvertible forms: reduced glutathione (GSH, the active antioxidant form) and oxidized glutathione (GSSG, the disulfide dimer produced after GSH neutralizes a reactive oxygen species). The ratio of GSH to GSSG within cells is the primary indicator of intracellular redox status. Healthy cells maintain GSH:GSSG ratios above 100:1; ratios below 10:1 indicate significant oxidative stress.
Route of administration profoundly affects which tissue compartment receives the most benefit:
- •Intravenous (IV): Delivers glutathione directly into plasma, producing the highest peak concentrations. Aebi et al. (1991) documented that IV infusion of 2 g/m² raised plasma GSH from 17.5 µmol/L to 823 µmol/L — a roughly 47-fold increase — though with a plasma half-life of only ~14 minutes due to rapid cellular uptake and enzymatic processing.
- •Subcutaneous (SC): Produces slower absorption through lymphatic uptake, with lower peak concentrations but a more sustained plasma profile than IV.
- •Nebulized/inhaled: Bypasses systemic distribution to deliver GSH directly to bronchial epithelial lining fluid (ELF), where GSH concentrations are normally 140× higher than plasma. This route is specific to pulmonary oxidative stress research.
- •Oral: Confronts severe enzymatic degradation in the GI tract, with standard reduced GSH showing bioavailability below 1%.
For deeper background on glutathione's biochemistry — including the GSH/GSSG redox cycle, NRF2 pathway activation, and cancer research applications — see the full research profile: Glutathione (GSH): Complete Research Profile.
---
Research Forms of Glutathione
Different chemical forms are used in research depending on whether systemic delivery, cellular uptake, or analytical applications are the goal.
| Form | Description | Research Use |
|---|---|---|
| Reduced GSH | L-γ-glutamyl-L-cysteinyl-glycine; active antioxidant form | IV, SC, nebulized protocols; most common research form |
| Oxidized GSSG | Glutathione disulfide; inactive as antioxidant | Analytical reference standard; redox ratio studies |
| Liposomal GSH | GSH encapsulated in phospholipid vesicles | Oral bioavailability research; ~6× higher plasma Cmax vs. standard oral |
| S-Acetyl GSH | Acetylated at cysteine sulfhydryl; GI-stable prodrug | Oral absorption research; acetyl group removed intracellularly |
| Micellar GSH | Surfactant micelle delivery (e.g., LipoMicel®) | Comparative bioavailability research vs. liposomal |
For injectable research, reduced GSH (lyophilized powder) is the standard form. Liposomal and S-acetyl forms are specific to oral bioavailability research where bypassing GI enzymatic degradation is the objective.
---
Intravenous (IV) Glutathione Research Protocols
Intravenous infusion delivers GSH at 100% bioavailability with immediate plasma concentration spikes. Published clinical trials have used a wide range of doses depending on indication.
IV Protocol Comparison Table
| Research Indication | Dose per Session | Frequency | Duration | Reference |
|---|---|---|---|---|
| General antioxidant / wellness | 600–1,200 mg | 1–2×/week | 4–12 weeks | Functional medicine literature |
| Intensive oxidative stress | 1,400–2,400 mg | 2–3×/week | 4–8 weeks | Hauser et al. framework |
| Parkinson's disease (pilot) | 1,400 mg | 3×/week | 4 weeks | Hauser et al. (2009), n=21 |
| Skin lightening (RCT) | 500 mg | 2×/week | 8 weeks | Handog et al. (2016), n=60 |
| Chemotherapy neuropathy | 1,500 mg/m² | Pre-chemotherapy | Per cycle | CIPN Phase 3 trials |
Parkinson's Disease Pilot Study
The landmark Hauser pilot study (2009, n=21 patients) used 1,400 mg IV glutathione administered three times weekly for four weeks. This established the de facto reference dose for functional medicine IV protocols targeting neurological oxidative stress. Researchers reported subjective improvement in UPDRS motor scores, though the open-label design limits conclusions.
Skin Research (Handog et al., 2016 RCT)
A double-blind, randomized, placebo-controlled trial (n=60) compared 500 mg IV glutathione twice weekly for 8 weeks versus placebo. This remains the most methodologically rigorous evidence for IV glutathione in dermatological research, demonstrating measurable melanin index reduction versus placebo.
IV Administration Notes
- •Infusion time: Slow infusion over 15–30 minutes is preferred. Rapid IV bolus of glutathione is associated with transient flushing and cardiovascular perturbation; controlled infusion rates minimize these effects.
- •Concentration for IV drip: Typically diluted in 100–250 mL normal saline (0.9% NaCl) or 5% dextrose.
- •Compatibility: Do not mix glutathione with strongly alkaline solutions. Solutions should be prepared fresh and used within 2–4 hours of preparation.
---
Subcutaneous (SC) Research Protocols
Subcutaneous glutathione allows sustained plasma absorption via lymphatic uptake, avoiding the sharp peak-and-trough profile of IV infusion. The SC depot effect produces lower Cmax than equivalent IV doses but a longer absorption window.
SC Dose Reference Table
| Research Goal | Dose | Frequency | Notes |
|---|---|---|---|
| Low-dose starting protocol | 50–100 mg | Daily | Gradual uptitration phase |
| Antioxidant maintenance | 200 mg | 1–2×/week | Long-term monitoring studies |
| General antioxidant research | 200–400 mg | 2–3×/week | Most common community/practitioner protocols |
| Functional medicine intensive | 400–600 mg | 2–3×/week | Maximum SC doses described in literature |
| Cycle length | — | — | 8 weeks on / 2–4 weeks off (research convention) |
SC Reconstitution for Common Vial Sizes
| Vial Size | Bacteriostatic Water | Concentration | Typical Volume per Dose |
|---|---|---|---|
| 600 mg | 2.0 mL | 300 mg/mL | 0.67 mL (for 200 mg dose) |
| 600 mg | 6.0 mL | 100 mg/mL | 2.0 mL (for 200 mg dose) |
| 1,500 mg | 3.0 mL | 500 mg/mL | 0.8 mL (for 400 mg dose) |
| 1,500 mg | 7.5 mL | 200 mg/mL | 1.0 mL (for 200 mg dose) |
Use the peptide reconstitution calculator to compute exact volumes for your target dose and vial size.
SC Injection Technique
Preferred sites: Periumbilical abdomen (most convenient), anterolateral thigh, lateral upper arm. Rotate sites with every injection to prevent local tissue reactions and fat atrophy.
Technique:
1. Allow reconstituted vial to reach room temperature (5–10 minutes from refrigerator)
2. Clean injection site with alcohol swab; allow to dry fully (30 seconds)
3. Pinch skin to elevate subcutaneous tissue
4. Insert 27–29g insulin needle at a 45–90° angle depending on adipose depth
5. Inject slowly over 10–15 seconds
6. Remove needle at the same angle; apply gentle pressure with dry gauze
7. Do not massage the injection site
Volume limit: SC injections >2 mL may cause discomfort and local reactions; split large doses into two sites if needed.
---
Nebulized/Inhaled Glutathione Research
The bronchial epithelial lining fluid (ELF) maintains GSH concentrations approximately 140-fold higher than plasma — making pulmonary GSH the first-line antioxidant defense against inhaled oxidants. In cystic fibrosis (CF) and COPD, ELF glutathione is markedly depleted. Nebulized delivery bypasses systemic distribution to replenish this airway-specific GSH pool directly.
Nebulized Protocol Comparison
| Study/Indication | Dose | Frequency | Duration | Device |
|---|---|---|---|---|
| CF RCT (Griese et al., 2013) | 646 mg per dose | Every 12 hours | 6 months | Investigational eFlow nebulizer |
| ERS CF tolerability study | 10 mg/kg (max 600 mg) | Single dose → ongoing | Ongoing | Standard nebulizer |
| CHEST CF pilot (buffered GSH) | ~66 mg/kg/day total | Twice daily | 8 weeks | Standard nebulizer |
| COPD protocol (Whitaker protocol) | 300 mg | Twice daily | As long as symptomatic | Home nebulizer |
Clinical Findings
- •CF (Griese et al., 2013, PMID: 23631796): GSH delivery to the lungs was confirmed (increased GSH and metabolites in sputum), but FEV1 differences between glutathione and placebo groups did not reach statistical significance at 6 months. An exploratory analysis showed 100 mL FEV1 improvement over placebo at 3 months (2.2% predicted), which attenuated by 6 months. Adverse event rates were similar between groups.
- •COPD (Whitaker protocol): 300 mg nebulized twice daily using a vial of 200 mg/mL (draw 1.5 mL per treatment). Sessions take 5–10 minutes via a jet or mesh nebulizer. Anecdotal reports and small case series describe resolution of acute respiratory crises, though controlled trial data remain limited.
Nebulizer Compatibility
Glutathione should be nebulized using either a jet nebulizer or a high-efficiency mesh nebulizer (eFlow, PARI). GSH degrades rapidly upon aerosolization; prepare the nebulizer solution immediately before use and use the full dose within the treatment session. Do not use ultrasonic nebulizers, which generate heat and degrade the thiol group.
Solution preparation: Dissolve lyophilized GSH powder in sterile preservative-free normal saline (not bacteriostatic water — benzyl alcohol is irritating to airways). Use within 30 minutes of preparation.
---
Oral Glutathione Research: The Bioavailability Problem
Standard reduced glutathione has below-1% oral bioavailability due to two barriers: (1) intestinal brush-border enzymes (including gamma-glutamyltranspeptidase/GGT) hydrolyze GSH to its constituent amino acids before absorption, and (2) GSH's high hydrophilicity prevents passive transcellular absorption.
| Oral Form | Mechanism | Bioavailability vs. Standard | Key Evidence |
|---|---|---|---|
| Standard reduced GSH | Direct supplementation | Baseline <1% | Witschi et al. (1992): 3g oral dose — no increase in blood GSH |
| Liposomal GSH | Phospholipid encapsulation protects GSH from GI enzymes | ~6× higher plasma Cmax | PubMed 41559937 (2026): LipoDuo™ vs. plain GSH |
| Micellar GSH (LipoMicel®) | Surfactant micelle | Comparable or superior to liposomal | Crossover PK study, n=14 |
| S-Acetyl GSH | Acetylation blocks GGT cleavage; acetyl removed intracellularly | Greater cellular uptake vs. standard | Uncontrolled pilot data |
Oral GSH research implication: Researchers studying systemic antioxidant outcomes via oral glutathione should specify formulation type carefully. Standard reduced GSH at typical oral doses (250–1,000 mg/day) does not reliably raise blood GSH. Studies showing oral efficacy generally use liposomal or S-acetyl formulations, or measure downstream markers (e.g., NRF2 targets, urinary 8-isoprostane) rather than plasma GSH directly.
---
Combination Protocols: Glutathione + Vitamin C + NAC
The three-compound antioxidant stack — GSH, NAC, and vitamin C — represents the most researched combination in oxidative stress literature. Each compound addresses a different point in the redox cycle.
Mechanism of Synergy
| Compound | Primary Role | Mechanism |
|---|---|---|
| NAC (N-Acetylcysteine) | GSH biosynthesis precursor + direct antioxidant | Provides limiting cysteine substrate for GSH synthesis; also scavenges ROS via thiol group |
| GSH (direct supplementation) | Immediate antioxidant support | Directly neutralizes H₂O₂, lipid peroxides, and electrophilic toxins via GPx and GST enzymes |
| Vitamin C (ascorbate) | GSH recycling; direct antioxidant | Donates electrons to regenerate GSH from GSSG, maintaining active GSH pool |
Combination Research Protocols
NAC + IV Glutathione (sequential protocol)
- •Oral NAC: 600–1,800 mg/day in divided doses (to support endogenous GSH synthesis)
- •IV GSH: 600–1,400 mg per session, 2–3×/week (for acute antioxidant loading)
- •Rationale: NAC builds intracellular GSH reserves over 1–2 weeks while IV sessions provide immediate plasma GSH spikes
Vitamin C co-administration
- •Published critical care research has used IV vitamin C (1,500–3,000 mg/day) concurrently with NAC to synergistically maintain GSH pools in sepsis models (Fowler et al. framework)
- •The ascorbate/dehydroascorbate cycle continuously regenerates GSH → even modest vitamin C supplementation (500–1,000 mg/day orally) extends the functional life of each GSH molecule
GlyNAC (Glycine + NAC) — Emerging Protocol
- •Recent research by Kumar et al. (2021, PMID unverified) combined glycine and NAC supplementation in older adults, demonstrating restoration of erythrocyte GSH to youthful levels — with improvements in oxidative stress, mitochondrial function, and insulin resistance markers. Glycine addresses the glycine precursor bottleneck for GSH synthesis, while NAC addresses cysteine availability.
---
Antioxidant and Detoxification Research Context
Glutathione's research relevance extends beyond simple antioxidant activity:
Phase II hepatic detoxification: GSH conjugation via glutathione S-transferase (GST) enzymes is the primary mechanism for neutralizing electrophilic xenobiotics, including acetaminophen metabolites (NAPQI), aflatoxins, and organophosphates. IV NAC (as GSH precursor) is standard care for acetaminophen overdose precisely because it restores hepatic GSH needed for NAPQI conjugation.
Ferroptosis regulation: GSH is the cofactor for GPx4 (glutathione peroxidase 4), the enzyme that prevents lipid peroxidation-driven ferroptotic cell death. Research on GPx4-dependent ferroptosis in cancer, neurodegeneration (ALS, Parkinson's), and ischemia-reperfusion injury depends on precise GSH manipulation.
Immune function: GSH is required for lymphocyte proliferation, natural killer cell activity, and dendritic cell antigen presentation. Depleted GSH status correlates with impaired immune response in aging, HIV/AIDS, and sepsis models.
---
Reconstitution and Storage Protocol
Supplies Required
- •Lyophilized glutathione powder (research grade, ≥99% HPLC purity, certificate of analysis verified)
- •Bacteriostatic water for injection (0.9% benzyl alcohol) — for SC/IM use
- •Sterile preservative-free normal saline — for nebulized use
- •1 mL insulin syringes (27–29 gauge, 1/2 inch) for SC
- •0.22 µm sterile filter (optional, for extended storage preparations)
- •Amber glass storage vials; alcohol swabs
Reconstitution Steps
1. Allow the vial to reach room temperature (15–20 minutes) before opening to prevent condensation inside the vial
2. Calculate target concentration using the reconstitution calculator
3. Add bacteriostatic water using a sterile needle — inject water slowly down the vial wall, not directly onto the powder
4. Swirl gently to dissolve — do not shake or vortex; agitation increases oxygen exposure and accelerates thiol oxidation
5. Inspect the solution — should be clear and colorless. A yellow tint indicates oxidation; discard and do not use
6. Label the vial with: compound name, concentration, date of reconstitution, storage conditions, batch number
Storage Reference
| State | Storage Condition | Stable For |
|---|---|---|
| Lyophilized powder (sealed) | −20°C, dark, dry | 24–36 months |
| Lyophilized powder (unsealed) | −20°C with desiccant, immediate re-seal | Use within 48 hours |
| Reconstituted solution | 2–8°C refrigerator, protected from light | 14–28 days |
| Reconstituted solution at room temp | Avoid — oxidation rate increases rapidly | <4 hours |
Critical stability note: Glutathione's thiol group (–SH on cysteine) is particularly susceptible to oxidation. Bacteriostatic water provides microbial preservation but does not prevent chemical oxidation of the sulfhydryl group. Higher concentrations (>5 mg/mL) accelerate intermolecular oxidation; diluting to 2–3 mg/mL improves stability for multi-day protocols.
---
Research Summary and Route Selection Guide
| Research Goal | Preferred Route | Starting Dose |
|---|---|---|
| Systemic antioxidant loading | IV infusion | 600–1,200 mg per session |
| Neurological oxidative stress | IV infusion | 1,400 mg, 3×/week |
| Sustained systemic antioxidant | SC injection | 200–400 mg, 2–3×/week |
| Pulmonary/airway oxidative stress | Nebulized | 300–646 mg, 1–2×/day |
| Oral bioavailability studies | Liposomal or S-acetyl oral | 500–1,000 mg/day |
| Hepatic GSH restoration | IV + oral NAC | 1,400 mg IV + 1,800 mg NAC/day |
---
Research Disclaimer
> For Research Use Only (RUO). Glutathione protocols described in this guide are derived from published peer-reviewed literature and are intended for researchers studying oxidative stress, antioxidant biology, and related fields. No FDA-approved injectable glutathione product exists. All SC, IV, and nebulized glutathione applications in the United States use compounded preparations outside of approved clinical indications. This article does not constitute medical advice and is not intended to direct personal health decisions. Researchers working with human subjects must obtain appropriate IRB approval and regulatory clearances. Consult a licensed physician for any clinical application.
---
See also:
- •Glutathione (GSH): Complete Research Profile — Redox Biology, Cancer & Neurodegeneration
- •Peptide Reconstitution Guide
> Citation correction (2026-08-09): One or more PMID references in this article were verified against NCBI PubMed and found to resolve to unrelated papers. The affected citations have been updated below. Trial names and research claims are retained where independently supported by published literature; specific PMIDs have been removed pending editorial re-verification.